1. Market Research
  2. > Pharmaceutical Market Trends
  3. > EnVivo Pharmaceuticals - Product Pipeline Review - 2013

EnVivo Pharmaceuticals - Product Pipeline Review - 2013

  • December 2013
  • -
  • Global Markets Direct
  • -
  • 43 pages

EnVivo Pharmaceuticals - Product Pipeline Review - 2013

Summary

Global Market Direct’s pharmaceuticals report, “EnVivo Pharmaceuticals - Product Pipeline Review - 2013” provides data on the EnVivo Pharmaceuticals’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, EnVivo Pharmaceuticals’s corporate website, SEC filings, investor presentations and featured press releases, both from EnVivo Pharmaceuticals and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- EnVivo Pharmaceuticals - Brief EnVivo Pharmaceuticals overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of EnVivo Pharmaceuticals human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of EnVivo Pharmaceuticals with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the EnVivo Pharmaceuticals’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate EnVivo Pharmaceuticals’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of EnVivo Pharmaceuticals in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the EnVivo Pharmaceuticals’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with EnVivo Pharmaceuticals.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of EnVivo Pharmaceuticals and identify potential opportunities in those areas.

Table Of Contents

EnVivo Pharmaceuticals - Product Pipeline Review - 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
EnVivo Pharmaceuticals Snapshot 5
EnVivo Pharmaceuticals Overview 5
Key Information 5
Key Facts 5
EnVivo Pharmaceuticals - Research and Development Overview 6
Key Therapeutic Areas 6
EnVivo Pharmaceuticals - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
EnVivo Pharmaceuticals - Pipeline Products Glance 11
EnVivo Pharmaceuticals - Late Stage Pipeline Products 11
Phase III Products/Combination Treatment Modalities 11
EnVivo Pharmaceuticals - Clinical Stage Pipeline Products 12
Phase II Products/Combination Treatment Modalities 12
Phase I Products/Combination Treatment Modalities 13
EnVivo Pharmaceuticals - Early Stage Pipeline Products 14
Preclinical Products/Combination Treatment Modalities 14
Discovery Products/Combination Treatment Modalities 15
EnVivo Pharmaceuticals - Drug Profiles 16
EVP-6124 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
EVP-0962 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
EVP-0334 20
Product Description 20
Mechanism of Action 20
RandD Progress 20
EVP-6308 22
Product Description 22
Mechanism of Action 22
RandD Progress 22
EVP-0015962 23
Product Description 23
Mechanism of Action 23
RandD Progress 23
EVP-4473 24
Product Description 24
Mechanism of Action 24
RandD Progress 24
Exploratory Program 1 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
Exploratory Program 2 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
GSM Follow On 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
Selective HDAC Inhibitor 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
EnVivo Pharmaceuticals - Pipeline Analysis 29
EnVivo Pharmaceuticals - Pipeline Products by Therapeutic Class 29
EnVivo Pharmaceuticals - Pipeline Products by Target 31
EnVivo Pharmaceuticals - Pipeline Products by Route of Administration 33
EnVivo Pharmaceuticals - Pipeline Products by Molecule Type 34
EnVivo Pharmaceuticals - Pipeline Products by Mechanism of Action 35
EnVivo Pharmaceuticals - Recent Pipeline Updates 37
EnVivo Pharmaceuticals - Dormant Projects 40
EnVivo Pharmaceuticals - Locations And Subsidiaries 41
Head Office 41
Appendix 42
Methodology 42
Coverage 42
Secondary Research 42
Primary Research 42
Expert Panel Validation 42
Contact Us 43
Disclaimer 43



List of Tables

EnVivo Pharmaceuticals, Key Information 5
EnVivo Pharmaceuticals, Key Facts 5
EnVivo Pharmaceuticals - Pipeline by Indication, 2013 8
EnVivo Pharmaceuticals - Pipeline by Stage of Development, 2013 9
EnVivo Pharmaceuticals - Monotherapy Products in Pipeline, 2013 10
EnVivo Pharmaceuticals - Phase III, 2013 11
EnVivo Pharmaceuticals - Phase II, 2013 12
EnVivo Pharmaceuticals - Phase I, 2013 13
EnVivo Pharmaceuticals - Preclinical, 2013 14
EnVivo Pharmaceuticals - Discovery, 2013 15
EnVivo Pharmaceuticals - Pipeline by Therapeutic Class, 2013 30
EnVivo Pharmaceuticals - Pipeline by Target, 2013 32
EnVivo Pharmaceuticals - Pipeline by Route of Administration, 2013 33
EnVivo Pharmaceuticals - Pipeline by Molecule Type, 2013 34
EnVivo Pharmaceuticals - Pipeline Products by Mechanism of Action, 2013 36
EnVivo Pharmaceuticals - Recent Pipeline Updates, 2013 37
EnVivo Pharmaceuticals - Dormant Developmental Projects,2013 40



List of Figures

EnVivo Pharmaceuticals - Pipeline by Top 10 Indication, 2013 7
EnVivo Pharmaceuticals - Pipeline by Stage of Development, 2013 9
EnVivo Pharmaceuticals - Monotherapy Products in Pipeline, 2013 10
EnVivo Pharmaceuticals - Pipeline by Top 10 Therapeutic Class, 2013 29
EnVivo Pharmaceuticals - Pipeline by Top 10 Target, 2013 31
EnVivo Pharmaceuticals - Pipeline by Top 10 Route of Administration, 2013 33
EnVivo Pharmaceuticals - Pipeline by Top 10 Molecule Type, 2013 34
EnVivo Pharmaceuticals - Pipeline Products by Top 10 Mechanism of Action, 2013 35



Companies Mentioned

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016 Summary Global Markets ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016 Summary Global Markets ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.